Le cluster Chien-Hsing Chang - Robert M Sharkey
| 000023 (2012) | Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. | |
| 000094 (2006) | Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. | |
| 000129 (2003) | Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. | |
| 000022 (2012) | Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). | |
| 000095 (2006) | Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. | |
| 000060 (2009) | Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. | |
| 000085 (2007) | Paraneoplastic ACTH secretion: bronchial carcinoid overlooked by planar indium-111 pentetreotide scintigraphy and accurately localized by SPECT/CT acquisition. | |
| 000116 (2005) | Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. | |
| 000127 (2003) | Voxeldoes: a computer program for 3-D dose calculation in therapeutic nuclear medicine. |
| This area was generated with Dilib version V0.5.76. |  |